Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients
Status:
Unknown status
Trial end date:
2019-02-27
Target enrollment:
Participant gender:
Summary
Investigators hypothesize that administration of ketamine for pain relief in sickle cell
patients with vaso-occlusive crisis early on will lead to a more rapid improvement in pain
score and less narcotic requirement.